Previous Close | 3.1000 |
Open | 3.0000 |
Bid | 2.9900 x 2200 |
Ask | 3.1600 x 1400 |
Day's Range | 2.9850 - 3.1450 |
52 Week Range | 1.3100 - 6.3300 |
Volume | |
Avg. Volume | 1,722,006 |
Market Cap | 579.389M |
Beta (5Y Monthly) | 1.50 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for LXRX
The big shareholder groups in Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) have power over the company. Institutions...
Biotech stocks have been through an extended lean patch, making them ideal candidates for a strong rebound. Verrica (VRCA): Approval of its viral skin disease treatment could transform the company into a commercial-stage biopharma. Amicus (FOLD): Pompe disease treatment approval opens up huge market opportunity for the biopharma. Athersys (ATHX): Potential approval for Japanese licensee would provide additional financing options. Nanobiotix (NBTX): Stock could be in for a reversal if ASCO abstra
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) entered into a loan facility with Oxford Finance LLC for 0 million to support commercial preparations and the potential launch of sotagliflozin in heart failure. The loan facility consists of four tranches, each maturing in March 2027. An initial $25 million tranche was funded at closing. The second $25 million tranche is available before August 31, contingent upon the acceptance of filing by the FDA of Lexicon's planned resubmission of sotagliflozin fo